AGN:CSE; AGNPF:OTCQB; AGN0:XFRA

Algernon Pharmaceuticals Inc.

Algernon is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for its lead drug NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

AGN:CSE AGNPF:OTCQB AGN0:XFRA

View Company News

Visit Company Website

Expert Comments:

Expert Says Biotech Co. Is a ‘Strong Buy’ After Phase 2 Study
(8/2/22)

Study Review Shows Greater Promise for Biopharma Co.'s Cough Treatment
(8/1/22)

Additional Study Review Reveals Patients Coughed Much Less
(7/28/22)

A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought.

Clive Maund, CliveMaund.com

(7/28/22)

"Algernon Pharmaceuticals Inc. came out with very good news this morning that the data from its Phase 2 study of ifenprodil is much better than expected. This is thought likely to get the stock moving again, and so we are considered to be at another good buy spot here."

André Uddin, Research Capital Corporation

(7/28/22)

"After conducting additional statistical review of the Phase 2a data in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, key opinion leader Dr. Jacky Smith noted that Algernon Pharmaceuticals Inc.'s cough data showed a significant improvement in mean objective 24-hour and waking cough counts after four and 12 weeks. . .it is our belief that it would be logical to develop ifenprodil for two indications: in IPF patients and also in IPF patients who have chronic cough."

Drug Repurposing Co. Provides Opportunity for High Rewards
(7/20/22)

Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough that met its endpoint and demonstrated promising initial efficacy. Research Capital Corp. advised that it is maintaining its CA$25.00/share price target and "Speculative Buy" rating on the company.

André Uddin, Research Capital Corporation

(7/18/22)

"Algernon Pharmaceuticals Inc. reported topline results of a Phase 2a trial with ifenprodil in idiopathic pulmonary fibrosis (IPF) patients with chronic cough. The IPF data hit its endpoint, showing promising initial efficacy. . .we recommend investors with a higher risk tolerance to aggressively purchase the stock."

Pharma Looks To Improve Potential Psychedelic Stroke Drug
(7/11/22)

Clive Maund, CliveMaund.com

(6/1/22)

"Algernon Pharmaceuticals Inc. is at a very good price and looks like it is shaping up for a breakout into a new bull market. This is a stock that is made much more attractive by the fact that it only has about 1.6M shares in issue as a result of a recent 1 for 100 share rollback. . .the stock is only at about 6% of the price at its 2016 peak."

Tech Startup Not Dabbling in Dabbl Acquisition
(3/4/22)

Clive Maund, CliveMaund.com

(2/2/22)

"We can see entry and exit points on the latest three-month chart of Algernon Pharmaceuticals Inc. stock and how it has reacted back in a satisfactory manner to another good buy spot, with the technical setup now very positive. The time has thus arrived to buy back the position we sold at a much higher price; it is rated a Strong buy again here, especially as the broad stock market is on the up again."

André Uddin, Research Capital Corporation

(1/28/22)

"For Algernon Pharmaceuticals Inc., the results of the ongoing Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough (Q2/22) represent an important near-term catalyst investors should watch. . .we believe the company is back on track and focused on developing its pipeline. We consider Algernon's current valuation favorable from a risk-reward standpoint."

More Expert Comments

Clive Maund, CliveMaund.com (1/19/22) "As we can see on its latest six-month chart, Algernon Pharmaceuticals Inc.'s stock has soared. . .we have certainly done well with this, having about doubled our money in a month."

	Bob Moriarty, 321 Gold (1/18/22) "Algernon Pharmaceuticals Inc. has a lot of potential, and I placed my bet with shares bought in the open market. . .the company has a lot of good things in the works, and there should be a constant flow of news. It's the kind of company that could be a $500M market cap in a takeout after success in any one of several drug trials."

Clive Maund, CliveMaund.com (1/12/22) "Long-term charts show Algernon Pharmaceuticals Inc. stock to be very cheap. As it now has only 1.6M shares in issue after a 1 for 100 rollback, it has big upside potential. . .the company remains a Buy here and especially on any minor dips, if any."

Clive Maund, CliveMaund.com (12/22/21) "Algernon Pharmaceuticals Inc. stock has now arrived at what looks like a long-term cyclical low at the support at its late 2019 lows, which is a good point for it to turn, and that's what it looks like it is in the process of doing. . .the fundamentals of the company are believed to be positive. The conclusion is that Algernon is rated an attractive Speculative Buy here."

Clive Maund, CliveMaund.com (12/12/21) "Algernon Pharmaceuticals Inc. has some good things going on. The stock looks like it is at or close to a cyclical low, especially as volume has built up dramatically over the past month in a manner that is characteristic of a bottom, with upside volume kicking in in recent days. . .we could soon see some good gains in this stock."

	André Uddin, Research Capital Corporation (12/6/21) "Algernon Pharmaceuticals Inc.'s Ifenprodil is in a Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough. . .the company expects to complete patient enrollment of the study by 2021E, with results anticipated in Q2/22. . .Algernon is a Phase 2-stage drug development company, yet it has a market cap of CA$7M. We believe its risk/reward profile is attractive."

André Uddin, Research Capital Corporation (8/4/21) Algernon Pharmaceuticals Inc. has decided to terminate the development of Ifenprodil for COVID-19. . .we agree with management that the risk-benefit profile of the COVID-19 program does not justify its continuation; we view the company's move as wise. . .Algernon is switching focus to the idiopathic pulmonary fibrosis/chronic cough indication."

Sam Riches, Weekend Dispensary (5/22/21) "Algernon Pharmaceuticals Inc. says it received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its planned Phase 1 clinical trial, which is set to begin later this year with the U.K.-based Hammersmith Medicines Research. . .Algernon believes its approach could potentially lead to a breakthrough therapy designation from the FDA, which enables priority review and can fast track the clinical trial process."

	André Uddin, Research Capital Corporation (5/10/21) "Algernon Pharmaceuticals Inc. has recently filed an end-of-Phase 2 meeting request with the U.S. Food and Drug Administration to discuss advancing ifenprodil to the Phase 3 part of the Phase 2b/3 trial in COVID-19. . .ifenprodil is in a Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough, for which results are expected in H2/21. DMT, a repurposed psychedelic compound, is expected to enter into a Phase 1 trial in stroke in H2/21."

André Uddin, Research Capital Corporation (3/1/21) "The database of the Phase 2b part of Algernon Pharmaceuticals Inc.'s Phase 2b/3 trial with ifenprodil in COVID-19 is to be locked for analysis on March 5, 2021; final results are expected to be disclosed shortly thereafter. Results of a Phase 2a trial with ifenprodil in idiopathic pulmonary fibrosis/chronic cough are expected in Q2/21 or Q3/21 for early chronic cough data and Q4/21 for full study data."

André Uddin, Research Capital Corporation (2/2/21) "Algernon Pharmaceuticals Inc. has established a program to repurpose a psychedelic compound, DMT, for stroke. . .the company is to continue a number of preclinical studies with DMT for stroke and is looking to file an investigational new drug application with the U.S. Food and Drug Administration based on DMT's historical data of Phase 1 clinical trials and new preclinical data generated by Algernon."

Clive Maund, CliveMaund.com (2/1/21) "Algernon Pharmaceuticals Inc. is looking like a Buy again here as it is at the bottom of the shallow uptrend that has developed from the December low, and a stop may be placed beneath the lower rail of the channel. An additional reason for buying the company here that may lead to a bigger move is the good news out of it this morning that it is commencing clinical research with a psychedelic drug for stroke treatment."

Clive Maund, CliveMaund.com (12/28/20) "The good news with Algernon Pharmaceuticals Inc. is that the stock has now arrived at a much stronger long-term support level in a deeply oversold state, so the least we can expect is a significant bounce from here. On Thursday there was a moderately bullish candle on strong volume with it closing well off the lows, which suggests that it may be reversing here or at least have hit bottom."

	André Uddin, Research Capital Corporation (12/15/20) "Algernon Pharmaceuticals Inc. reports interim results of a COVID-19 Phase 2b/3 trial with Ifenprodil. . .The results showed two positive early trends in high-dose ifenprodil at Day 15: (i) fewer patients required mechanical ventilation and (ii) the reduction of the NEWS score (used to monitor patient status) was quicker, which could potentially translate to a faster recovery down the road. . .We are maintaining our SPECULATIVE BUY rating and TP of $0.80/share. AGN remains a high risk high reward investment opportunity."

Clive Maund, CliveMaund.com (12/8/20) "Algernon Pharmaceuticals Inc. is now in a vigorous uptrend. It has paused for a rest in recent days with a small bull Pennant believed to be forming. Current light volume and strong Accumulation line suggest that another upleg is imminent."

All Penny Stocks (8/24/20) "What a spectacular run junior biotech Algernon Pharmaceuticals Inc. has made since late-November. The stock run-up is largely predicated on one virus, COVID-19. With a brief pullback over the last few months, we think it is time to revisit this stock as the technical stars may be aligning for one more major push higher."

	André Uddin, Research Capital Corporation (8/19/20) "We are initiating coverage of Algernon Pharmaceuticals Inc. with a Speculative Buy recommendation and a target price of $0.80/share. . .Algernon is focused on developing repurposed small molecules for new disease indications – these drug candidates have been already approved in ROW markets (but not approved in the U.S. or Europe). . .Algernon's lead product, ifenprodil (a marketed drug in Japan for circulatory disorders) is being repurposed for COVID-19, idiopathic pulmonary fibrosis (IPF) and chronic cough."

Experts Following This Company

Clive Maund – CliveMaund.com
	Bob Moriarty, Author – 321 Gold
	Penny Queen, Mother, Investor and Social Media Leader
	André Uddin – Research Capital Corporation

Company News

8/3/2022 – Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

7/28/2022 – Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

7/18/2022 – Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

7/11/2022 – Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

7/7/2022 – Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

7/5/2022 – Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

7/4/2022 – Algernon Pharmaceuticals Announces Closing of Public Offering of Units

6/27/2022 – Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

6/22/2022 – Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

6/21/2022 – Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended

6/15/2022 – Algernon Pharmaceuticals Announces Public Offering of Units

6/13/2022 – Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights

	Advancing new drug treatments for billion dollar global disease markets.
	Conducting multiple phase II clinical trials
	Experienced management team & globally recognized medical advisory board

catalyst Calendar

Q2 2021	U,S, FDA End-of-Phase 2 COVID-19 Study Meeting, Q2, 2021
Q4 2021	Phase 2 trial for IPF and chronic cough data expected Q4, 2021.
Q4 2021	Phase 1 Study planned for DMT, Q4 2021